FOR AUSTRALIAN HEALTHCARE PROFESSIONALS
Can healthcare professionals do more to prevent shingles in adults?
Only ~ 1 in 3 adults aged ≥65 years have received at least one dose of SHINGRIX vaccine on the NIP * 1
SCAN THE QR CODE TO LEARN MORE ABOUT SHINGRIX
START THE CONVERSATION ABOUT SHINGLES VACCINATION
Recombinant Varicella Zoster Virus glycoprotein E antigen( AS01B adjuvanted vaccine)
*
Proportion of adults ≥65 years of age( ≥50 years of age for Indigenous adults) who were eligible for SHINGRIX under the NIP and received at least one vaccine dose between 1 November 2023 and 31 October 2024. Most current publicly available Australian Immunisation Register( AIR) data as of 10 November 2024. This data is updated quarterly by NCIRS. SHINGRIX NIP eligibility is estimated based on information available in the AIR regarding age, Indigenous status and prior Zostavax vaccination. SHINGRIX NIP eligibility for non-Indigenous adults aged < 65 years and Aboriginal and Torres Strait Islander adults aged < 50 years could not be calculated, as information on immunocompromise was not available in the AIR.
Indication 2: SHINGRIX is indicated for the prevention of herpes zoster( HZ) and post-herpetic neuralgia in: adults 50 years of age or older, and in adults 18 years of age or older at increased risk of HZ. Contraindication 2: Hypersensitivity to the active substances or to any component of the vaccine.
PBS Information: SHINGRIX is listed on the National Immunisation Program( NIP) for Aboriginal and Torres Strait Islander adults aged ≥50 years, for all individuals aged ≥65 years and for adults aged ≥18 years with some immunocompromising medical risk conditions. Refer to NIP schedule or your State or Territory Health department.
Please review Product Information before prescribing. Product Information can be accessed at www. gsk. com. au / shingrix or by scanning the QR code.
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems.
References: 1. National Centre for Immunisation Research and Surveillance( NCIRS). Zoster( shingles) vaccination data. Available at: ncirs. org. au / immunisation-coverage-data-and-reports / zoster-shingles-vaccination-data [ Accessed March 2025 ]. 2. SHINGRIX Approved Product Information. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109 GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trade marks are owned by or licensed to the GSK group of companies. © 2025 GSK group of companies or its licensor. PM-AU-SGX-JRNA-250001. Date of approval: March 2025.